What efforts are made to extend tigecycline's patent?

How does the FDA let companies keep a drug on the market after the original patent runs out?
The FDA can award a “patent term extension” (PTE) up to 5 years for drugs that lost patent life while awaiting approval. The extension compensates for time spent in clinical development and regulatory review. For tigecycline, a PTE application would be filed with the FDA and the USPTO, potentially adding a few years to market exclusivity beyond the original 20‑year patent period [1].

Can new uses keep a drug protected longer?
Patents are specific to the claims made. By filing additional patents that cover new indications, combination therapies, or novel dosing schedules, a company can extend legal protection for those specific uses. This strategy is common for antibiotics that find new activity against resistant strains or work synergistically with other drugs [2].

What about new formulations or delivery methods?
Patents on alternative formulations—such as a prolonged‑release tablet, a nebulized aerosol, or a novel liposomal carrier—can generate separate exclusivity periods. Even if the core chemical structure is patented, a different formulation may warrant a fresh patent application and can delay generic entry [3].

Does the Hatch‑Waxman Act’s 6‑year cap help here?
The Hatch‑Waxman Act allows a maximum of 6 years of PTE, but the actual duration depends on the time lost in the approval process. If tigecycline’s original patent expired before the drug was approved, the company could claim a PTE that covers the remaining patent life up to the 6‑year limit [4].

Are there other exclusivity programs that apply?
The FDA grants a 5‑year data exclusivity period for new chemical entities, which bars generic manufacturers from relying on the sponsor’s clinical data for that time. If tigecycline qualifies for “orphan drug” status for a rare bacterial infection, the sponsor could receive an additional 7‑year market exclusivity [5]. These exclusivities stack with the PTE to extend protection.

When does tigecycline’s original patent expire?
Tigecycline was first approved in 2005, and its primary patents, filed in the early 2000s, expire around 2025–2026. If the company files PTE or new patents before that date, it can extend market exclusivity beyond the standard expiration [6].

How do competitors try to counter or work around these extensions?
Generic manufacturers monitor for “patent challenges” or “parallel filing” strategies that allow them to file for their own patents on similar compounds. They also seek “exclusivity gaps” by proving that the drug’s formulation or usage is not adequately covered by the sponsor’s patents [7].

What legal challenges might threaten these extensions?
Patent infringement suits can force a company to abandon or modify its claims. Additionally, the FDA can refuse a PTE if the drug failed to meet safety or efficacy standards, or if the extension would undermine public health. Patent holders must defend their claims in court and maintain robust evidence of the drug’s distinctiveness [8].

---

Sources
[1] https://www.fda.gov/drugs/guidance-comprehensive-information-chemical-and-biological-entities/patent-term-extension
[2] https://www.uspto.gov/patents/basics/what-patent
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/formulation-development-and-approval
[4] https://www.fda.gov/drugs/pharmaceuticals/patent-term-extension
[5] https://www.fda.gov/drugs/orphan-drug-designation-program
[6] https://www.fda.gov/drugs/drug-approval-process/fda-drug-approval-history
[7] https://www.wipo.int/patents/en/
[8] https://www.fda.gov/drugs/clinical-trials-and-investigational-new-drug-application